Thromboembolism News and Research

RSS

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.

22 Oct 2018

New standard of care aims to prevent deaths caused by largely preventable blood clots

A new nationally agreed standard of care released today (Thursday) aims to reduce the tens of thousands of Australian lives put at risk each year by largely preventable blood clots, which kill four times more people than road accidents.

12 Oct 2018

New inflammatory biomarker correlates with increased thrombosis risk in cancer patients

Cancer patients are known to have an increased risk of thrombosis. As part of the CATS study, MedUni Vienna researchers have now investigated a correlation between an activated immune system in cancer patients and their risk of thrombosis.

26 Sep 2018

Recurrence risk of VTE appears similar for patients with cancer and those with unprovoked VTE

Patients with venous thromboembolism carry a high risk of recurrence. Accordingly, a 16-year Danish prospective cohort study of nearly 74,000 patients with incident VTE concluded that the risk of recurrence is substantial.

25 Sep 2018

Genes predicting person's height may provide clues about causes of varicose veins

A person's height and certain genes that predict height are associated with varicose veins and may provide clues about what causes this condition and ways to prevent and treat it, according to new research in the American Heart Association's journal Circulation.

24 Sep 2018

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.

19 Sep 2018

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Exelixis, Inc. today announced that the National Comprehensive Cancer Network updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets.

7 Sep 2018

Shionogi launches Mulpleta in the U.S for safe, effective treatment of thrombocytopenia

Shionogi & Co., Ltd. announced today that Mulpleta (lusutrombopag), a once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure, is now available throughout the United States.

30 Aug 2018

Antithrombin drug does not reduce risk of myocardial infarction, stroke in heart failure patients

The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival, myocardial infarction and stroke after an episode of worsening heart failure in patients with heart failure, sinus rhythm, and coronary artery disease, according to late breaking results from the COMMANDER HF trial presented today in a Hot Line Session at ESC Congress 2018 and with simultaneous publication in NEJM.

27 Aug 2018

Oral anticoagulant use after hospital discharge may offer protection from non-fatal blood clots

The use of an oral anticoagulant medicine in medically ill patients for 45 days following their discharge from the hospital reduces the rate of non-fatal symptomatic blood clots with no impact on fatal blood clots, according to late breaking results from the MARINER trial presented today in a Hot Line Session at ESC Congress 2018 and published in The New England Journal of Medicine.

27 Aug 2018

FDA approves first vaginal ring contraceptive that can be used for one year

The U.S. Food and Drug Administration today approved Annovera (segesterone acetate and ethinyl estradiol vaginal system), which is a combined hormonal contraceptive for women of reproductive age used to prevent pregnancy and is the first vaginal ring contraceptive that can be used for an entire year.

10 Aug 2018

Transgender individuals may be at higher risk for cardiovascular disease

Transgender individuals may be at higher risk for myocardial infarction and death due to cardiovascular disease, according to several studies.

3 Aug 2018

Depression, antidepressant use linked with higher risk of venous thromboembolism

In the first review of its kind, new research has found that depression and the use of antidepressants are each associated with an increased risk of venous thromboembolism.

24 Jul 2018

Researchers develop new model for predicting cancer-associated venous thrombosis

In collaboration with international partners, a study group from the Medical University of Vienna has developed a new model for predicting cancer-associated venous thrombosis/pulmonary embolism.

11 Jul 2018

Direct oral anticoagulants associated with reduced risks of major bleeding

New drugs known as direct oral anticoagulants used to treat serious blood clots are associated with reduced risks of major bleeding compared with the older anti-clotting drug, warfarin, finds a study in The BMJ today.

5 Jul 2018

Risk of heart attacks, strokes and vascular occlusions found to be higher in cancer patients

It is well known that pre-existing cancer is a significant risk factor for venous thrombosis. What was hitherto unclear was whether cancer also has a negative impact upon the risk of heart attacks, strokes or occlusions of peripheral arteries.

25 Jun 2018

Oral drug reduces venous thromboembolism recurrence among cancer patients

Research from the University of Warwick indicates that taking a tablet a day can help treat cancer patients of a potentially deadly condition.

11 May 2018

Study shows cardiovascular problems are more common in uterine cancer survivors

A new study in the Journal of the National Cancer Institute indicates that survivors of uterine cancer are more likely to experience cardiovascular problems years after treatment.

8 May 2018

International research consortium identifies 22 new genetic risk factors for stroke

An international research consortium studying 520,000 individuals from around the world has identified 22 new genetic risk factors for stroke, thus tripling the number of gene regions known to affect stroke risk.

13 Mar 2018

Research finds correlation between perioperative air travel and high risk of venous thromboembolism

New research presented at the 2018 Annual Meeting of the American Academy of Orthopaedic Surgeons found a correlation between flying following hip or knee arthroplasty and an increased risk of venous thromboembolism.

6 Mar 2018